Pygeum is a bark extract from the African cherry tree (Prunus africana) used primarily to ease urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH). A Cochrane systematic review found that men taking pygeum were more than twice as likely to report improvement in overall urinary symptoms compared with those taking a placebo, with nighttime urination reduced by roughly a fifth and urinary flow improved by nearly a quarter.1PubMed Central. Pygeum africanum for benign prostatic hyperplasia That evidence base, while promising, is older and smaller than what exists for some competing prostate supplements, and the story of pygeum extends well beyond the prostate.
Where Pygeum Comes From
Prunus africana is a large evergreen tree native to the mountain forests of sub-Saharan Africa. Its bark has been used in African traditional medicine for centuries, with decoctions taken orally for a wide range of ailments including stomach pain, chest pain, malaria, kidney disease, and urinary complaints.2PubMed. The African cherry: A review of the botany, traditional uses, phytochemistry, and biological activities of Prunus africana (Hook.f.) Kalkman In East Africa, the bark has also been used to manage respiratory conditions, diabetes, and hypertension, while in West Africa, particularly Cameroon, it has a history in wound healing and mental health treatment.3PubMed Central. A Comprehensive Review of Ethnomedicinal Uses, Phytochemistry, Pharmacology, and Toxicity of Prunus africana (Hook. F.) Kalkman from Africa The modern supplement industry, however, zeroes in almost exclusively on the prostate. Most pygeum products sold in Western markets are standardized lipophilic (fat-soluble) extracts of the bark, and the compounds thought to do the heavy lifting include beta-sitosterol, ferulic acid esters, and atraric acid.4Journal of Pharmaceutical and Biomedical Analysis. Chemical comparison of Prunus africana bark and pygeum products marketed for prostate health
What the Clinical Evidence Shows for BPH Symptoms
The strongest evidence for pygeum centers on relieving lower urinary tract symptoms tied to BPH. The Cochrane review pooled data from 18 trials involving over 1,500 men and found a moderately large overall improvement in urologic symptoms and urinary flow measures. In quantitative terms, men taking pygeum saw nighttime urination drop by about 19%, residual urine volume (the amount left in the bladder after urinating) fall by about 24%, and peak urine flow increase by about 23%.1PubMed Central. Pygeum africanum for benign prostatic hyperplasia A separate systematic meta-analysis published in The American Journal of Medicine arrived at essentially the same numbers, reinforcing the consistency of the finding.5The American Journal of Medicine. Pygeum africanum for Benign Prostatic Hyperplasia: A Systematic Review and Quantitative Meta-Analysis
Those improvements are real but moderate. A roughly one-fifth reduction in nighttime bathroom trips, for instance, could mean going from five trips a night to four, which is noticeable but not life-changing for everyone. It is also worth knowing that most of the trials in these reviews were conducted in the 1970s through the 1990s, with relatively small sample sizes and short durations. Modern, large-scale, head-to-head comparisons with prescription BPH drugs are largely absent. So while the direction of the evidence is positive, how pygeum stacks up against the alpha-blockers or 5-alpha reductase inhibitors your urologist might prescribe remains an open question.
How Pygeum Works in the Body
Pygeum bark contains a cocktail of active compounds, and researchers believe multiple mechanisms contribute to its effects rather than one single pathway. The two best-studied involve hormone metabolism and inflammation.
On the hormonal side, pygeum extract inhibits an enzyme called 5-alpha reductase, which converts testosterone into a more potent form called dihydrotestosterone (DHT). DHT is the main hormonal driver of prostate growth. In laboratory testing, pygeum extract showed strong, dose-dependent inhibition of this enzyme, with activity beginning at low concentrations.6Phytomedicine. Inhibition of 5 alpha-reductase and aromatase by PHL-00801 Prostatonin, a combination of PY102 Pygeum africanum and UR102 Urtica dioica extracts The same study found pygeum also inhibited aromatase, the enzyme that converts androgens into estrogen. Both DHT and estrogen play roles in prostate enlargement, so blocking both conversion pathways could theoretically slow or reduce the process. This dual mechanism mirrors, at least conceptually, what prescription 5-alpha reductase inhibitors like finasteride do, though pygeum’s potency in a living human body is far weaker than a pharmaceutical drug.
On the inflammation side, an in vitro study using human immune cells found that a standardized pygeum bark extract significantly lowered several inflammatory signaling molecules, including IL-6, TNF-alpha, and IL-2.7PubMed Central. Anti-Inflammatory Potential of Pygeum africanum Bark Extract: An In Vitro Study of Cytokine Release by Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells Chronic low-grade inflammation in the prostate is thought to worsen BPH symptoms, so tamping down that inflammation could contribute to symptom relief. This anti-inflammatory activity may also explain why pygeum was traditionally used for conditions far removed from the prostate, like chest pain and respiratory illness.
Pygeum and Prostate Cancer
A natural follow-up question: if pygeum helps an enlarged prostate, does it do anything for prostate cancer? The honest answer is that the research is extremely early-stage and limited to lab and animal work, not human trials. One study using prostate cancer cell lines found that an ethanolic extract of pygeum inhibited the growth of two types of prostate cancer cells, induced programmed cell death, and showed binding activity at both estrogen and androgen receptors.8PubMed. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo Another lab study found that pygeum had stronger anti-growth and cell-death effects on stromal cells from BPH tissue compared to non-BPH tissue, particularly targeting a type of smooth muscle cell that is more abundant in enlarged prostates.9PubMed. Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)
These findings are interesting mechanistically, but killing cancer cells in a dish and treating cancer in a person are different things entirely. No clinical trial has tested pygeum as a prostate cancer treatment, and no medical guideline recommends it for that purpose. If you see pygeum marketed with language hinting at cancer prevention, be skeptical. The science does not support that claim at this point.
Dosage and What to Look For
Most clinical trials have used a total daily dose of 100 mg of a standardized lipophilic bark extract, typically containing about 14% triterpenes and 0.5% n-docosanol (a long-chain fatty alcohol). This dose has been tested in two regimens: 50 mg taken twice a day, or 100 mg taken once a day. A randomized, double-blind trial directly comparing these two schedules found them equally effective over a two-month period, followed by a ten-month open-label extension at 100 mg once daily.10PubMed. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension The once-daily option is simpler and appears to work just as well.
If you are shopping for a pygeum supplement, “standardized extract” on the label matters. Raw bark powder and standardized lipophilic extract are not interchangeable. The clinical evidence is based on the latter. Products that list only generic “pygeum bark” without mentioning standardization may or may not contain the same active compound profile. There is also a known consistency problem: an analytical chemistry study comparing marketed pygeum products to actual Prunus africana bark found measurable differences in their chemical profiles, meaning not all products deliver the same compounds at the same concentrations.4Journal of Pharmaceutical and Biomedical Analysis. Chemical comparison of Prunus africana bark and pygeum products marketed for prostate health This is a broader problem in the supplement industry, but it is particularly relevant for pygeum because the active compounds are sensitive to the extraction method.
Side Effects and Safety
One of the more reassuring findings from the clinical literature is that pygeum appears to be well tolerated. In the Cochrane review, adverse effects were described as mild and comparable to placebo.1PubMed Central. Pygeum africanum for benign prostatic hyperplasia The meta-analysis in The American Journal of Medicine likewise noted that side effects were mild and similar in frequency to those experienced by men on placebo.5The American Journal of Medicine. Pygeum africanum for Benign Prostatic Hyperplasia: A Systematic Review and Quantitative Meta-Analysis The most commonly reported complaints across trials were gastrointestinal issues, mainly nausea, stomach discomfort, and occasional diarrhea. These tended to be transient and rarely led to study dropouts.
That said, the safety data comes with the same caveat as the efficacy data: most trials were short-term and relatively small. Long-term safety over years of daily use has not been rigorously studied. And because pygeum has hormonal activity, specifically its ability to inhibit 5-alpha reductase and aromatase, there are theoretical concerns about interactions with hormone-sensitive conditions or medications. If you take finasteride, dutasteride, or any other drug that affects androgen or estrogen metabolism, mentioning pygeum to your prescriber is a reasonable step. The same goes for anyone being treated for a hormone-sensitive cancer.
Pygeum Compared with Saw Palmetto
Saw palmetto (Serenoa repens) is the other dominant herbal supplement sold for prostate health, and the two are frequently combined in multi-ingredient prostate formulas. Both work partly through 5-alpha reductase inhibition, but the depth and quality of their evidence bases differ. Saw palmetto has a much larger body of clinical trials, including several large, well-designed randomized controlled trials. The results for saw palmetto have been decidedly mixed: high-quality trials have found it performs no better than placebo for BPH symptoms. Pygeum’s trial literature is smaller and older, which makes direct comparison tricky. The Cochrane review was more favorable to pygeum than the comparable Cochrane review is to saw palmetto, but the pygeum trials had methodological limitations that could inflate apparent benefits.
In practice, many people try both, sometimes together. Whether combining them offers any additional benefit over either alone is not well studied. A few older trials used fixed combinations of pygeum and nettle root extract, but these tell you about the combination product, not about adding pygeum to saw palmetto specifically. If you have been taking saw palmetto without much improvement, switching to pygeum or adding it is a reasonable experiment, but keep expectations moderate and give it at least six to eight weeks before evaluating.
Claims About Sexual Health
Some pygeum products are marketed with claims about improving sexual function or boosting seminal fluid production. The sexual health angle comes partly from traditional use and partly from the fact that prostate secretions contribute to seminal volume, so a healthier prostate could theoretically improve that. A review comparing pygeum with another African botanical noted pygeum’s primary role as a BPH remedy with anti-inflammatory and anti-androgenic effects, rather than as a direct sexual enhancer.11Journal of Pharmaceutical Research International. Comparative Effects of Mondia whitei and Prunus africana in Male Sexual Health: A Comprehensive Review If your urinary symptoms are disrupting sleep and daily comfort, and pygeum eases those symptoms, your quality of life and by extension your sexual well-being could improve indirectly. But the idea that pygeum is a standalone aphrodisiac or a reliable way to increase ejaculate volume does not have clinical trial support.
Who Should and Shouldn’t Try Pygeum
Pygeum is most relevant for men with mild-to-moderate BPH symptoms who prefer to try a supplement before (or alongside) prescription medication. The typical candidate is someone who gets up a few times a night to urinate, feels like their bladder does not empty completely, or notices a weaker urine stream. For mild symptoms, 100 mg daily of a standardized extract is a low-risk option to try for a couple of months.
Pygeum is less appropriate as a standalone approach for severe BPH symptoms. If you are retaining significant amounts of urine, experiencing recurrent urinary tract infections, or noticing blood in your urine, those symptoms need medical evaluation, not a supplement. Pygeum also has not been studied in women, and its hormonal activity makes it a poor candidate for casual experimentation outside of BPH. Young men without prostate issues have no evidence-based reason to take it. And anyone with a known prostate cancer diagnosis should not use pygeum as a substitute for oncologic care, regardless of the intriguing lab data on cancer cells.
The Conservation Problem
There is an ethical dimension to pygeum that rarely makes it onto supplement labels. Prunus africana has been so heavily harvested from its native habitat to supply the global supplement and pharmaceutical market that it is now listed under CITES (the Convention on International Trade in Endangered Species), the same treaty that regulates trade in elephant ivory and tiger parts. The bark harvesting is often destructive: stripping too much bark kills the tree, and demand has outpaced the tree’s slow natural regeneration in many regions of Cameroon, Kenya, and Madagascar.12PubMed Central. Prunus africana (Hook.f.) Kalkman: the overexploitation of a medicinal plant species and its legal context
The trade also raises questions about resource rights. Local African communities that have used the bark for generations often receive little benefit from the international trade, while large-scale harvesters and exporters profit. Efforts at sustainable cultivation and fair-trade sourcing exist, but they remain small relative to the overall market. If you use pygeum regularly, looking for products that claim certified sustainable sourcing is one small way to push the industry in a better direction, though verifying those claims independently is difficult. It is one of those cases where a supplement’s ecological footprint is easy to ignore at the point of purchase but genuinely consequential on the other end of the supply chain.
Product Quality and What Research Still Needs to Answer
One of the less-discussed challenges with pygeum is product variability. As already noted, chemical analysis of off-the-shelf products has shown inconsistency with the actual bark’s compound profile.4Journal of Pharmaceutical and Biomedical Analysis. Chemical comparison of Prunus africana bark and pygeum products marketed for prostate health This is not unique to pygeum — it plagues most herbal supplements — but it is worth remembering when interpreting your own experience. If one brand did nothing, a different standardized product might perform differently, and if one brand worked, switching to a cheaper option might not replicate the result.
The bigger gap is in the clinical research itself. The existing trials are mostly decades old, used varying formulations, and were conducted before modern standards for trial registration and reporting were widespread. What the field needs are large, modern, well-controlled trials that compare pygeum head-to-head with prescription BPH medications and with placebo, using validated symptom scores and long follow-up periods. Until those trials are conducted, pygeum sits in a common limbo for herbal supplements: the evidence is encouraging enough that plenty of people find it worth trying, but not strong enough for most urologists to recommend it as a first-line treatment. Whether future research elevates it or deflates the current optimism is genuinely uncertain.